Treffer 1 - 10 von 10 für Suche 'Brendan D Curti', Suchdauer: 0,05s
Treffer weiter einschränken
-
1
Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab von William L Redmond, Walter J Urba, John Cha, Yoshinobu Koguchi, Brendan D Curti, Noriko Iwamoto, Takashi Shimada, Shu-Ching Chang, Brian D Piening
Veröffentlicht 2021-10-01
Artikel -
2
Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance von Marcus A. Couey, R. Bryan Bell, Ashish A. Patel, Meghan C. Romba, Marka R. Crittenden, Brendan D. Curti, Walter J. Urba, Rom S. Leidner
Veröffentlicht 2019-07-01
Artikel -
3
Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study von Gregory A Daniels, Sigrun Hallmeyer, Mark Grose, Jon Richards, Mark Faries, Brendan D Curti, Kim A Margolin, Yiwei Zhang, Lynn Feun, Anlong Li, John R Hyngstrom, Robert H I Andtbacka
Veröffentlicht 2022-12-01
Artikel -
4
Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells von Rebekka Duhen, Carmen Ballesteros-Merino, Alexandra K. Frye, Eric Tran, Venkatesh Rajamanickam, Shu-Ching Chang, Yoshinobu Koguchi, Carlo B. Bifulco, Brady Bernard, Rom S. Leidner, Brendan D. Curti, Bernard A. Fox, Walter J. Urba, R. Bryan Bell, Andrew D. Weinberg
Veröffentlicht 2021-02-01
Artikel -
5
Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition von Elizabeth I. Buchbinder, Janice P. Dutcher, Gregory A. Daniels, Brendan D. Curti, Sapna P. Patel, Shernan G. Holtan, Gerald P. Miletello, Mayer N. Fishman, Rene Gonzalez, Joseph I. Clark, John M. Richart, Christopher D. Lao, Scott S. Tykodi, Ann W. Silk, David F. McDermott
Veröffentlicht 2019-02-01
Artikel -
6
HDAC inhibition prevents transgene expression downregulation and loss-of-function in T-cell-receptor-transduced T cells von Tamson V. Moore, Gina M. Scurti, Matthew DeJong, Siao-Yi Wang, Annika V. Dalheim, Courtney R. Wagner, Kelli A. Hutchens, Jodi J. Speiser, Constantine V. Godellas, Chris Fountain, Jessica Fleser, Tarsem Moudgil, Mallory Thomas, David Murray, Brendan D. Curti, Joseph I. Clark, Bernard A. Fox, Michael I. Nishimura
Veröffentlicht 2021-03-01
Artikel -
7
Systemic immunostimulation induces glucocorticoid-mediated thymic involution succeeded by rebound hyperplasia which is impaired in aged recipients von Craig P. Collins, Lam T. Khuat, Gail D. Sckisel, Logan V. Vick, Christine M. Minnar, Cordelia Dunai, Catherine T. Le, Brendan D. Curti, Marka Crittenden, Alexander Merleev, Michael Sheng, Nelson J. Chao, Emanual Maverakis, Spencer R. Rosario, Arta M. Monjazeb, Bruce R. Blazar, Dan L. Longo, Robert J. Canter, William J. Murphy, William J. Murphy
Veröffentlicht 2024-09-01
Artikel -
8
A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma von Sandra Aung, Sigrun Hallmeyer, David F. McDermott, Joseph I. Clark, Howard L. Kaufman, Gregory A. Daniels, Sapna P. Patel, John M. Kirkwood, Ryan J. Sullivan, Marc S. Ernstoff, Brendan D. Curti, Elizabeth I. Buchbinder, Rene Gonzalez, John M. Richart, Anasuya Gunturi, Jessica Perritt, Janice Dutcher, Girald P. Miletello, Joe Lutzky, Michael A. Morse
Veröffentlicht 2016-11-01
Artikel -
9
Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in pat... von Christy Ralph, Sumati Gupta, Matthew Zibelman, Brendan D Curti, Kevin J Harrington, Steven J O'Day, Andrew G Hill, David C Campbell, Gavin M Wright, David E Gerber, Jonathan E Rosenberg, Jaime R Merchan, Charles M Rudin, Hardev S Pandha, Wallace L Akerley, Daphne Day, Timothy D Clay, Ross R Jennens, Yixin Ren, Emmett V Schmidt, Lisa Guttman
Veröffentlicht 2023-01-01
Artikel -
10
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas von Thomas F Gajewski, John A Thompson, Sanjay Goel, Brendan D Curti, Elisabeth I Heath, Olivier Rixe, David C Smith, Celine Jacquemont, Tycel Phillips, Martin Gutierrez, Sahar Ansari, Andrew L Coveler, Svetomir N Markovic, Timothy M Kuzel, Amitkumar N Mehta, David L Bajor, Hun Ju Lee, Ajay K Gopal, Paolo Caimi, Ariel Topletz-Erickson, Peigen Zhou, Michael W Schmitt, Juneko E Grilley-Olson
Veröffentlicht 2023-06-01
Artikel